S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:CYCN

Cyclerion Therapeutics - CYCN Stock Forecast, Price & News

$0.93
-0.05 (-5.11%)
(As of 08/12/2022 05:16 PM ET)
Add
Compare
Today's Range
$0.91
$0.96
50-Day Range
$0.47
$1.15
52-Week Range
$0.46
$3.62
Volume
202,295 shs
Average Volume
197,333 shs
Market Capitalization
$40.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Cyclerion Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,021.3% Upside
$10.50 Price Target
Short Interest
Healthy
0.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.09mentions of Cyclerion Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.11) to ($1.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

525th out of 1,117 stocks

Pharmaceutical Preparations Industry

258th out of 550 stocks

CYCN stock logo

About Cyclerion Therapeutics (NASDAQ:CYCN) Stock

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Cyclerion Therapeutics Trading Up 2.1 %

CYCN Stock opened at $0.98 on Friday. The company's 50 day simple moving average is $0.73 and its 200-day simple moving average is $0.88. Cyclerion Therapeutics has a 12 month low of $0.46 and a 12 month high of $3.62.

Receive CYCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYCN Stock News Headlines

Cyclerion Therapeutics reports Q1 results
Cyclerion Therapeutics Inc(CYCN)
See More Headlines
Receive CYCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYCN Company Calendar

Last Earnings
11/09/2021
Today
8/12/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYCN
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+1,029.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-51,650,000.00
Net Margins
-2,551.69%
Pretax Margin
-2,551.74%

Debt

Sales & Book Value

Annual Sales
$3.94 million
Book Value
$0.58 per share

Miscellaneous

Free Float
39,451,000
Market Cap
$40.40 million
Optionable
Not Optionable
Beta
2.31

Key Executives

  • Dr. Peter M. Hecht Ph.D. (Age 58)
    CEO & Director
    Comp: $108.22k
  • Ms. Cheryl Gault (Age 42)
    Chief Operating Officer
    Comp: $513.43k
  • Dr. Andreas Busch Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $669.36k
  • Ms. Anjeza Gjino (Age 39)
    CFO & Corp. Sec.
  • Dr. Todd Milne Ph.D.
    Sr. VP of External Innovation
  • Ms. Jessica Rennekamp
    Associate Director of Corp. Communications
  • Mr. Christopher Winrow Ph.D.
    Sr. Director of Clinical Devel. & Neuroscience Program Lead
  • Ms. Jennifer Chickering Ph.D.
    Sr. Director of Clinical Strategy













CYCN Stock - Frequently Asked Questions

Should I buy or sell Cyclerion Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclerion Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CYCN shares.
View CYCN analyst ratings
or view top-rated stocks.

What is Cyclerion Therapeutics' stock price forecast for 2022?

2 brokerages have issued 12 month price targets for Cyclerion Therapeutics' stock. Their CYCN share price forecasts range from $7.00 to $14.00. On average, they expect the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 1,021.3% from the stock's current price.
View analysts price targets for CYCN
or view top-rated stocks among Wall Street analysts.

How have CYCN shares performed in 2022?

Cyclerion Therapeutics' stock was trading at $1.72 at the beginning of the year. Since then, CYCN stock has decreased by 45.6% and is now trading at $0.9364.
View the best growth stocks for 2022 here
.

When is Cyclerion Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CYCN earnings forecast
.

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced its earnings results on Tuesday, November, 9th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.09. The company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $3 million. Cyclerion Therapeutics had a negative trailing twelve-month return on equity of 115.98% and a negative net margin of 2,551.69%.

What other stocks do shareholders of Cyclerion Therapeutics own?

What is Cyclerion Therapeutics' stock symbol?

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

Who are Cyclerion Therapeutics' major shareholders?

Cyclerion Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (5.84%), Franklin Resources Inc. (0.18%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Andreas Busch, Mark G Currie, Peter M Hecht, Peter M Hecht, Slate Path Capital Lp, Terrance Mcguire and William Huyett.
View institutional ownership trends
.

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclerion Therapeutics' stock price today?

One share of CYCN stock can currently be purchased for approximately $0.94.

How much money does Cyclerion Therapeutics make?

Cyclerion Therapeutics (NASDAQ:CYCN) has a market capitalization of $40.69 million and generates $3.94 million in revenue each year. The company earns $-51,650,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.

How can I contact Cyclerion Therapeutics?

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.cyclerion.com. The company can be reached via phone at (857) 327-8778 or via email at ir@cyclerion.com.

This page (NASDAQ:CYCN) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.